<DOC>
	<DOCNO>NCT01444742</DOCNO>
	<brief_summary>The goal clinical research study learn clofarabine give combination cytarabine help control myelodysplastic syndrome ( MDS ) disease could control standard therapy . The safety treatment also study . Clofarabine design interfere growth development cancer cell . Cytarabine design insert DNA ( genetic material cell ) cancer cell stop DNA repairing .</brief_summary>
	<brief_title>Clofarabine Plus Low-Dose Cytarabine Patients With Higher-Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Induction Cycles : If find eligible take part study , Days 1-5 cycle , receive clofarabine vein 1-2 hour . On Days 1-7 cycle , receive cytarabine injection skin several second 2 time day . You may receive 3 cycle dose schedule ( also call `` induction cycle '' ) . There 7 treatment day cycle total length one cycle ( include rest recovery period ) usually 4 8 week . Consolidation Cycles : After complete Induction Cycles , show response treatment , continue total 12 cycle therapy , call `` consolidation cycle '' . Not every participant may able receive 12 consolidation cycle . The actual number receive depend whether maintain response able tolerate ongoing therapy . There 4-8 week consolidation cycle depend side effect may blood count . During consolidation cycle receive clofarabine Days 1-3 vein 1-2 hour . You receive cytarabine injection skin several second 2 time day . Induction Consolidation Cycles : On day receive clofarabine cytarabine ( Days 1-5 induction Days 1-3 consolidation ) , clofarabine give 3-6 hour cytarabine injection . You teach give cytarabine injection . In case , leave clinic receiving clofarabine . You require record injection cytarabine diary unless receive treatment hospital . Study Visits : On Day 1 every cycle ( +/- 7 day ) : - You physical exam , include measurement weight vital sign . - Your performance status record . - Blood ( 1-2 teaspoon ) draw routine test . About 4 week start first cycle , may bone marrow aspirate check status disease . After , may repeat bone marrow aspirate doctor think need . It recommend stay Houston first 4 week treatment . After , need return Houston induction cycle . If continue consolidation receive treatment local oncologist . However , return Houston least every 3 month study visit . Length Study : You may continue take study drug 15 cycle . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Clofarabine FDA approve commercially available use pediatric patient acute lymphoblastic leukemia . Its use adult patient MDS investigational . Cytarabine FDA approve commercially available use patient acute myeloid leukemia ( AML ) . Up 80 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>1 . Age &gt; /= 18 year . 2 . Diagnosis MDS confirm within 10 week prior study entry accord World Health Organization ( WHO ) FAB criterion . Patients either eligible choose proceed stem cell transplant . 3 . MDS classify follow : refractory anemia excess blast ( RAEB1 ) ( 5 % 9 % BM blast ) ; RAEB2 ( 10 % 19 % BM Blasts ) ; chronic myelomonocytic leukemia ( CMML ) ( 5 % 19 % BM blast ) ; RAEBt ( 20 % 29 % BM blast ) AND/OR IPSS : intermediate2 high risk patient . 4 . No response , progression , relapse ( accord 2006 IWG criterion ; see section 8 detail ) follow least 4 cycle either azacitidine decitabine , follow least 2 cycle SGI110 , complete within last 2 year AND/OR intolerance azacitidine , decitabine , SGI110 define drugrelated &gt; /= grade 3 hepatic renal toxicity lead treatment discontinuation precede 2 year . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . 6 . Willing adhere comply prohibition restriction specify protocol . 7 . Patient ( patient 's legally authorize representative ) must sign informed consent document indicate patient understands purpose procedure require study willing participate study . 1 . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . 2 . Active infection adequately respond appropriate antibiotic ( i.e . ongoing temperature &gt; /= 38 degree Celsius ) . 3 . Total bilirubin &gt; /= 1.5 mg/dL relate hemolysis Gilbert 's disease . Patients total bilirubin &gt; /= 1.5 mg/dL 3 mg/dL eligible least 75 % bilirubin indirect . 4 . Alanine transaminase ( ALT/SGPT ) aspartate transaminase ( AST/SGOT ) &gt; /= 2.5 x upper limit normal . 5 . Serum creatinine &gt; 1.5 mg/dL . 6 . Female patient pregnant lactate . 7 . Patients reproductive potential unwilling follow contraception requirement ( include condom use male sexual partner , female : prescription oral contraceptive [ birth control pills ] , contraceptive injection , intrauterine device ( IUD ) , doublebarrier method [ spermicidal jelly foam condom diaphragm ] , contraceptive patch , surgical sterilization ) throughout study . 8 . Female patient reproductive potential negative urine blood betahuman chorionic gonadotropin ( beta HCG ) pregnancy test screening . 9 . Patients receive concurrent investigational agent chemotherapy , radiotherapy , immunotherapy . 10 . No prior treatment cytarabine clofarabine . Prior hydroxyurea control leukocytosis use hematopoietic growth factor ( eg , GCSF , GMCSF , procrit , aranesp , thrombopoietins ) allow time prior study consider best interest patient . 11 . Psychiatric illness social situation would limit patient 's ability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myeloproliferative Diseases</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>( MDS )</keyword>
	<keyword>Relapsing</keyword>
	<keyword>Refractory</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
</DOC>